
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech's financial position is solid, with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables as of the end of Q3 2025, providing a robust foundation for its continued growth and investment in pharmaceutical research. The incremental positive developments surrounding the global Phase 3 DYNASTY-Breast02 trial for candidate BNT323 signal potential advancements in its oncology pipeline, which is varied and consists of multiple innovative therapies. Additionally, the company’s continued innovation in its Covid-19 vaccine, demonstrated by improved immune responses against multiple SARS-CoV-2 sublineages in preclinical models, underscores BioNTech's commitment to addressing emerging infectious diseases, further enhancing its market position.
Bears say
The financial outlook for BioNTech exhibits several concerns that contribute to a negative assessment of its stock. With a projected full-year net loss per diluted share of €3.99 and a recorded net loss of €0.12 per diluted share for 3Q25, the company faces significant financial challenges. Furthermore, risks associated with potential negative data from multiple drug candidates, slower-than-expected market uptake, regulatory hurdles, and commercial risks impact investor confidence, particularly amidst the evolving COVID-19 vaccine landscape.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares